1. Home
  2. ARCT

as 05-28-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.

Founded: 2013 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 821.4M IPO Year: N/A
Target Price: $62.83 AVG Volume (30 days): 508.4K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.03 EPS Growth: N/A
52 Week Low/High: $17.52 - $43.81 Next Earning Date: 05-08-2024
Revenue: $124,526,000 Revenue Growth: -55.69%
Revenue Growth (this year): 11.19% Revenue Growth (next year): 40.23%

Stock Insider Trading Activity of Arcturus Therapeutics Holdings Inc. (ARCT)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Chivukula Pad ARCT Chief Scientific Officer & COO Mar 19 '24 Sell $35.01 8,565 $299,839.24 490,883 SEC Form 4
Chivukula Pad ARCT Chief Scientific Officer & COO Nov 1 '23 Sell $18.72 5,000 $93,601.50 499,448 SEC Form 4

Share on Social Networks: